Webinars

Overlooked: Addressing Malnutrition in People with Overweight and Obesity

How does malnutrition—including sarcopenic obesity—impact outcomes in people with overweight and obesity?

Presenter(s): Carley Rusch, PhD, RDN, LDN; Jillian Hyttenhove, MA, RD, CSOWM, LD, CHES; Kirk W Kerr, PhD

Date: 12 May 2026

Time: Noon-1 PM ET

Location: Live webinar

Continuing Education Credits: Nurse Contact 1.0 CE; Dietitian 1.0 CPEU

Summary

Malnutrition is not only a concern for underweight individuals; it is also a significant issue for those who are obese or overweight. This course will explore the factors that contribute to malnutrition in this population, the impact of sarcopenic obesity, and potential intervention strategies that address both obesity and malnutrition effectively.

Our expert speakers will:

  • Review the burden of malnutrition in patients with overweight and obesity and its impact on patient outcomes 
  • Define sarcopenic obesity and identify factors that contribute to the development of sarcopenia in adults with overweight and obesity 
  • Describe how health care providers can support patients with overweight and obesity and concurrent malnutrition
Webinar Flyer

Overlooked: Addressing Malnutrition in People with Overweight and Obesity 

Key Takeaways:

  • Both malnutrition and sarcopenia negatively impact outcomes such as survival, length of stay, risk for pressure injuries and recovery 
  • In patients with overweight and obesity, especially when pursuing intentional weight loss, prioritize malnutrition screening, monitoring lean body mass, individualized nutrition interventionx 

Related Questions:

  • Can people with overweight or obesity have signs of malnutrition (undernutrition)?
    Yes. A higher BMI does not rule out malnutrition risk or diagnosis as patients with elevated BMI can still meet screening and diagnostic criteria for malnutrition (undernutrition). Excess adipose tissue may also mask visible signs of muscle and fat loss, making malnutrition easier to miss.
  • Do GLP‑1 receptor agonists (GLP-1 RAs) influence dietary intake and nutrition status?
    GLP‑1 RAs are associated with reduced calorie intake versus placebo in studies, but there’s limited consensus on the best dietary strategy and uncertainty about how diet composition impacts muscle vs fat loss on these medications. People on these medications may be at higher risk for nutrient deficiencies. Therefore, monitoring nutritional adequacy should be prioritized.
  • Why is protein intake important during weight loss in people with obesity?
    Higher protein intake (>25% total calories) in adults is associated with greater fat loss and better fat-free mass retention during diet-induced weight loss compared with lower protein intake. Maintaining protein adequacy can help support muscle health.

Presenter Bio(s):

Carley Rusch, PhD, RDN, LDN

Adult Medical Science Liaison
Medical Affairs & Research
Abbott Nutrition 
Gainesville, FL, USA

Carley Rusch serves as a Medical Science Liaison in Medical Affairs & Research at Abbott, specializing in Adult Therapeutic Nutrition. Prior to joining Abbott, Dr Rusch completed her bachelor’s degree in Food Science and Human Nutrition at the University of Florida (UF), specializing in Dietetics. She earned her master’s degree and completed her dietetic internship through the MS-DI program at UF. During her dietetic training, she also served as a research coordinator on a variety of study protocols, including topics on gastrointestinal dysfunction, inflammation, pre- and probiotics, and the gut microbiome. She then went on to work as an inpatient dietitian at AdventHealth Orlando and served as a preceptor for their dietetic internship program. Her clinical experience spans a variety of disease states, such as cancer, gastrointestinal and neurological disorders, malnutrition, and critical care.

Following her time working in clinical practice, Dr Rusch completed her PhD in Nutritional Sciences at UF. Her doctoral research investigated the effect of the Mediterranean diet on improving constipation and intestinal inflammation in Parkinson’s disease. During her graduate programs, she has taught multiple undergraduate and graduate courses on nutrition, metabolism, and research methods. In 2020, she was awarded Recognized Young Dietitian of the Year by the Florida Academy of Nutrition and Dietetics. Dr Rusch has several publications in peer-reviewed journals and has been invited to present at national and international conferences.

Jillian Hyttenhove, MA, RD, CSOWM, LD, CHES

Medical Science Liaison
Medical Affairs & Research
Abbott Nutrition
Columbus, OH, USA

Jillian Hyttenhove is a Medical Science Liaison at Abbott Nutrition. Prior to joining Abbott, she worked in corporate wellness for several large national and global companies.

Jillian completed her bachelor’s degree in Dietetics at Bowling Green State University and her dietetic internship at East Carolina University. She went on to complete her Master of Arts in Health Education at East Carolina University as well. Following the completion of her dietetic internship, she served as the lead outpatient dietitian for all outpatient services at a community hospital in North Carolina. She then collaborated with a lead obesity specialist to create a comprehensive weight management program at the University of North Carolina, where she also served as a research dietitian on clinical trials.

Jillian is a Registered Dietitian, a Board-Certified Specialist in Obesity and Weight Management, and a Board-Certified Specialist in Health Education.

Kirk W Kerr, PhD

Senior Manager, Health Economics
Abbott Nutrition
Columbus, OH, USA

Kirk W Kerr, PhD, joined Abbott Nutrition’s Health Economics and Outcomes Research team in June 2019. While at Abbott, Kirk has researched the impact of nutrition-focused Quality Improvement programs in inpatient, outpatient, and surgical care settings. Before joining Abbott, Kirk worked in the FDA’s Center for Drug Evaluation and Research researching the impact of FDA policies on drug development, drug prices, and patient access to medicines. While at the FDA, he also provided economic support for the FDA’s Generic Drug User Fee (GDUFA) and Biosimilar User Fee (BsUFA) negotiating teams. He also worked as an economic consultant on antitrust and intellectual property matters. Kirk has a PhD and MA in Economics from Ohio State University, and BS and MA in Economics from the University of Missouri.

 

 

Category